Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorigerlimab - MacroGenics

Next Previous
Search
Drug Profile

Lorigerlimab - MacroGenics

Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART molecule

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
  • 20 Mar 2025 MacroGenics completes enrolment in the LORIKEET phase II trial for Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in United Kingdom, Spain, Puerto Rico, Poland, Georgia, France, Bulgaria, Belgium, USA (IV) (NCT05848011)
  • 20 Mar 2025 MacroGenics plans a phase II LINNET trial for Solid tumors (Late-stage disease, Second-line therapy or greater) in the US, Canada and South Korea in mid of 2025 (IV) (NCT06730347)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top